Beam And Verve Benefit From Buzz Around Base-Editing Therapies
Excitement Around Next-Gen Gene-Editing
Executive Summary
Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.
You may also be interested in...
Prime Medicine Launches With $315m To Fund New Approach To Gene Editing
The company sees its gene-editing technology, which it compares to a DNA “word processor,” as having potentially broad applicability.
Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
Finance Watch: ARCH Raises $1.85bn Venture Fund To Back Early-Stage Companies
Private Company Edition: The venture capital firm said it will back biopharma, diagnostics and other opportunities in health care. In addition to the Design and TScan mega-rounds, Verve raised $94m, Vera garnered $80m and Ixaka (formerly Rexgenero) closed a £40m ($54.7m) financing.